THE QUESTION, IN CONTEXT

A metabolic trial can produce several interesting numbers without testing several equally important claims. Body weight, glycated haemoglobin and cardiovascular events describe different aspects of health. A paper designed around one of them cannot silently become proof of the others. This distinction matters when search results group semaglutide, tirzepatide and newer investigational compounds under a single heading such as metabolic benefits. The heading is convenient; the evidence underneath it is more specific.

Three landmark research programmes illustrate the difference. STEP 1 examined semaglutide in adults with overweight or obesity without diabetes, with weight change among its primary outcomes. SURPASS-2 compared tirzepatide with semaglutide in people with type 2 diabetes, using change in glycated haemoglobin as its primary endpoint. SELECT studied cardiovascular outcomes in participants with established cardiovascular disease and overweight or obesity, without diabetes. These are not interchangeable samples of the same experiment. Each programme was built around a different research question.

A useful outcome map places every finding beside its population, measurement and observation period. It lets you see what a study actually contributes without dismissing useful findings or inflating them. The sections below explain how to build that map, why a composite endpoint needs unpacking and how to avoid treating a marker's movement as an automatic answer about symptoms, function or long-term events. It also helps explain why two credible trials can offer different, complementary pieces of a much larger picture.

Preparing the full guide…

The extended sections are available during your one-minute preview and with free email registration.

  1. Weight outcomes: a measurement with several possible summaries
  2. Glycaemic outcomes: do not exchange units or populations
  3. Clinical events: inspect the components of the composite
  4. Place benefits and burdens on the same outcome map
  5. Build a comparison that preserves the question
Full text is served after the reading access check.
FOLLOW THE EVIDENCE

Sources & further reading

Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.

  1. STEP 1: Once-weekly semaglutide in adults with overweight or obesityOriginal paper
  2. SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetesOriginal paper
  3. SELECT: Semaglutide and cardiovascular outcomes in obesity without diabetesOriginal paper
  4. FDA: Multiple endpoints in clinical trialsOfficial guidance
  5. Echo Research Hub: Incretin and metabolic receptor agonistsEcho hub
Educational information only. Evidence for an investigational medicine, formulation or application does not establish that a supplier’s research product is equivalent. Personal treatment questions belong with a qualified clinician.
KEEP READINGRead the trial before you rate the moleculeBody composition: what a weight-loss headline leaves unresolved